Abstract 2119P
Background
Malnutrition and weight loss have renowned prognostic value in patients (pts) with localised gastric cancer (GC). We analysed the association of weight loss and early nutritional intervention with outcomes in pts with advanced GC.
Methods
A retrospective cohort of non-resected metastatic GC pts treated with first-line chemotherapy (CT) at the Academic Hospital of Udine (2012-2022) was analysed. Biometric and nutritional parameters were evaluated at diagnosis and during treatment. The prognostic value of >10% weight loss 3 months (mo) after nutritional intervention was assessed. Nutritional interventions and scores (Prognostic Nutritional Index [PNI], neutrophil-lymphocyte ratio [NLR], platelet-lymphocyte ratio [PLR]), dichotomized as high/low per literature-derived cut-offs, were evaluated as predictors of overall survival (OS) and progression-free survival (PFS) with Cox regression model.
Results
100 pts were included (65 male), median age was 69 years. At CT start, 87.8% of pts had lost weight (>10% in 49.4%), with a median loss of 8 Kg. 55.7% of pts had low PNI, more than 60% high NLR and PLR. 71 pts underwent nutritional assessment (NA), 53.5% before CT start; median time from diagnosis to NA was 40 days. 51 pts had >1 NA, 31 pts >2 NA. At first NA, nutritional interventions consisted in oral supplements (53.4%), parenteral nutrition (28.2%) and counselling (59.2%). Overall, 49% of pts gained weight 3 mo after NA; 88.9% of pts’ PNI improved, >50% of NLR and PLR lowered. At disease progression, recorded in 96 pts, PLR and NLR increased significantly (60% vs 48% at 3 mo after NA and 70% vs 34%, respectively). In our cohort, median PFS was 5 mo and median OS was 9 mo. Low PNI (HR 2.05, p = 0.008), high NLR (HR 2.51, p <0.001) and PLR (HR 2.63, p <0.001) at CT start and a >10% weight loss (HR 3.05, p = 0.020) 3 mo after first NA were associated with worse OS. PLR improvement at 3 mo after first NA was associated with better OS (HR 0.46, p = 0.018).
Conclusions
These results underline the importance of early and efficient nutritional assessment and support in cancer pts. The prognostic value of PNI, NLR and PLR reinforces the importance of the interplay between immune system and weight loss for advanced GC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Puglisi: Financial Interests, Research Grant: AstraZeneca, Eisai; Financial Interests, Financially compensated role: AstraZeneca, Roche, Amgen, Lilly, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06